Friday, August 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Expresses Optimism for Lam Researchs Future Prospects

Elaine Mendonca by Elaine Mendonca
January 27, 2024
in Breaking News
0
Biotechnology Market Capitalization
0
SHARES
15
VIEWS
Share on FacebookShare on Twitter

On January 27, 2024, Toshiya Hari, an analyst at Goldman Sachs, expressed optimism about the future prospects of Lam Research (NASDAQ:LRCX). Hari maintained a Buy rating on the company’s stock and increased the price target from $700 to $912. This upward adjustment signifies a positive outlook on the stock, suggesting the anticipation of a higher future stock price.

Notably, various other analyst firms have also provided their price targets for Lam Research. The highest price target stands at $980, while the lowest is at $655. This range of expectations within the market showcases the diverse perspectives on the company’s potential.

Over the past year, a consensus has emerged among 22 analysts’ ratings, indicating a Moderate Buy sentiment. On average, these analysts predict a twelve-month price of $778.05, with the highest price target aligning with Hari’s revised target at $912.

Lam Research Corporation (LRCX) Stock Performance Declines: Factors and Analysis for Investors

On January 27, 2024, Lam Research Corporation (LRCX) experienced a decline in its stock performance. According to data from CNN Money, the price of LRCX shares decreased by $26.56 since the market last closed, representing a 3.07% drop. The stock closed at $839.04, which was already a significant decrease from its previous value. Furthermore, in after-hours trading, the stock dropped an additional $0.04. The decrease in LRCX’s stock price could be attributed to various factors, including a broader market downturn and negative news or developments related to Lam Research Corporation. Investors should conduct thorough research and analysis before making any investment decisions.

Lam Research Corporation (LRCX) Shows Stable Performance and Positive Growth in Key Financial Metrics on January 27, 2024

Lam Research Corporation (LRCX) has shown stable performance in its stock on January 27, 2024. The company’s total revenue for the past year was $17.43 billion, with $3.76 billion in the second quarter. LRCX’s total revenue has remained flat since the previous year, but there has been a 7.93% growth since the last quarter, indicating recent improvement in financial performance. Net income for the past year was $4.51 billion, with $954.27 million in the second quarter. Net income has remained stable since the previous year, but there has been a 7.54% increase since the last quarter, suggesting improved profitability. Earnings per share (EPS) for the past year was $33.21, increasing to $7.22 in the second quarter. EPS has remained flat since the previous year, but there has been an 8.35% growth since the last quarter, indicating improved profitability per share. Overall, LRCX’s stock performances on January 27, 2024, show positive signs of growth in key financial metrics, suggesting improved financial performance and contributing to the positive performance of its stock on that day.

Tags: LRCX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Markets and money

Bearish Sentiment Dominates Options Market for Super Micro Computer SMCI

Analysts Bullish on Rhythm Pharmaceuticals Growth Potential

Finance_Fiscal (2)

Goldman Sachs Analyst Maintains Neutral Rating for Seagate Technology Holdings with Increased Price Target

Recommended

Palantir Stock

Palantir Shares Face Valuation Pressures Despite Strong Earnings

9 months ago
BridgeBio Pharma Stock

BridgeBio Pharma Investors Await Critical Heart Drug Data

9 months ago
Ocugen Stock

Ocugen’s Fresh $130M Cushion Sets the Stage for a Data-Heavy July and a Pivotal Regulatory Filing

1 month ago
Airbnb Stock

Navigating Regulatory Headwinds and Innovation: Airbnb’s Strategic Crossroads

10 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Kioxia’s Unsettling Arithmetic: Record Profits, a $229 Million Verdict, and a Stock Still Searching for Its Floor

French Top Court Settles Disputes Over Expert Fees, Strike Notices and the AGS Wage Guarantee

MSCI World ETF: Index Provider Rewrites the Rulebook for Fast-Moving Stocks

Airbus’ Paradox: A Slightly Smaller Forecast That Nobody Seems to Mind

Almonty Industries Rebounds From Index-Driven Exit as Tungsten Calculus Shifts Westward

OHB’s Two-Faced Half-Year: Record Orders Mask a Profit Squeeze That Spooked the Market

Trending

Nel ASA Stock
Analysis

Nel ASA’s Two-Speed Story: Orders Accelerate While the P&L Keeps Bleeding

by Jackson Burston
August 7, 2026
0

The Norwegian electrolyser maker Nel ASA is living a split-screen reality. Its order intake just exploded by...

SANDISK Stock

SanDisk’s $94 Billion Backlog Can’t Bridge the Gap Between Record Results and a Disappointed Market

August 7, 2026
Bitcoin Stock

Payrolls Shrink, Rate-Cut Bets Return, and Crypto’s Plumbing Wins

August 7, 2026
Kioxia Stock

Kioxia’s Unsettling Arithmetic: Record Profits, a $229 Million Verdict, and a Stock Still Searching for Its Floor

August 7, 2026
FALLBACK Stock

French Top Court Settles Disputes Over Expert Fees, Strike Notices and the AGS Wage Guarantee

August 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Nel ASA’s Two-Speed Story: Orders Accelerate While the P&L Keeps Bleeding
  • SanDisk’s $94 Billion Backlog Can’t Bridge the Gap Between Record Results and a Disappointed Market
  • Payrolls Shrink, Rate-Cut Bets Return, and Crypto’s Plumbing Wins

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com